Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.



October 11, 2019

Jochen Reiser, MD, PhD, the chairperson of internal medicine, will be honored as a Hero in Medicine at the second annual Halo Awards on October 12.

July 8, 2019

Findings published today in the journal Science Translational Medicine suggest that a type of white blood cell called tumor associated macrophages that have been deceived by pancreatic cancer cells into not attacking them can be “reprogrammed” by a specially designed molecule that activates a protein found on their surfaces. 

June 5, 2018

Researchers at Rush have identified biomarkers that indicate which hip replacement patients are likely to suffer from destruction of bone tissue.

April 10, 2018

Osteoarthritis (OA) is one of the most common causes of chronic pain in the world. More than 30 million people in the United States alone suffer from OA, which can affect any moveable joint of the body, including the knees, hips, and hands. OA normally manifests itself as a breakdown of joint tissues, including degradation of cartilage.

May 11, 2018

Rush is helping lead a new health research accelerator that has launched in the Chicago area with nearly $35 million in funding from the NIH.

March 13, 2018

Stem cell treatments have potential to transform medicine. Experts in cancer, neurosurgery, orthopedics and pediatrics discuss the possibilities.

January 16, 2018

Rush researcher Susan Chubinskaya, PhD, is helping lead a study that aims to make space travel easier on astronauts, while providing insights for the rest of us here on Earth.

June 27, 2017

The number of cancer clinical trials at Rush doubled last year — from around 30 in early 2015 to nearly 150 by the end of 2016. And the focus of the research has broadened.

June 23, 2017

A study has found that the gene mutation that puts many black people at risk for chronic kidney disease requires higher than normal levels of a protein called suPAR to trigger the onset and progression of the disease.

June 19, 2017

A Rush study shows for the first time how dying cells ensure they will be replaced, and suggests a new approach to shrinking cancerous tumors.